Last reviewed · How we verify
NCT06104293
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
NA trial testing Grass Pollen Allergen Exposure in Allergic Rhinitis Due to Grass Pollen in 24 participants. Completed in 6 April 2023.
7 February 2023
Quick facts
| Lead sponsor | Alyatec |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | other |
| Enrollment | 24 |
| Start date | 16 November 2022 |
| Primary completion | 7 February 2023 |
| Estimated completion | 6 April 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Grass Pollen Allergen Exposure
Conditions studied
- Allergic Rhinitis Due to Grass Pollen — all drugs for Allergic Rhinitis Due to Grass Pollen →
Sponsor
Alyatec
Who can join
Adults 18 to 65, any sex, with Allergic Rhinitis Due to Grass Pollen. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to determine the optimal concentration of grass pollen allergens inducing rhinoconjunctivitis in subjects allergic to grass pollen in ALYATEC allergen exposure chamber. Four concentrations of grass pollen allergen (Phl p 5) are tested during 3-hour exposures: 0, 30, 60 and 90 ng/m3.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06104293
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allergic Rhinitis Due to Grass Pollen
Currently open trials in the same condition.
- NCT06061848 — Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT · Phase 2, PHASE3 · recruiting
Other Alyatec trials
Trials by the same sponsor.
- NCT06267261 — Efficacy of Face Mask in Reducing Respiratory Allergic Symptoms in Birch-allergic Subjects in ALYATEC Exposure Chamber · NA · completed
- NCT04583202 — Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Expo · NA · completed
- NCT03928561 — Efficacy of Air Cleaners in Asthmatics Allergic to Cat in ALYATEC Environmental Exposure Chamber · NA · completed
- NCT04641130 — Clinical Validation Study in Allergic Conjunctivitis to Birch Pollen During Allergen Challenge in ALYATEC EEC · NA · completed
- NCT04678063 — Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Cat Allergic Subjects With Asthma · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06104293 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alyatec
- Last refreshed: 27 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06104293.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing